Garo Armen - Protagenic Therapeutics Chairman of the Board
PTIX Stock | USD 1.64 0.07 4.46% |
Chairman
Dr. Garo H. Armen, Ph.D. is Chairman of the Board of the Company. He is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he cofounded in 1994. From mid2002 through 2004, he also served as Chairman of the Board of directors of the biopharmaceutical company Elan Corporationrationration, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies, and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community since 2016.
Age | 71 |
Tenure | 8 years |
Professional Marks | Ph.D |
Address | 149 Fifth Avenue, New York, NY, United States, 10010 |
Phone | 212 994 8200 |
Web | https://www.protagenic.com |
Garo Armen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Garo Armen against Protagenic Therapeutics stock is an integral part of due diligence when investing in Protagenic Therapeutics. Garo Armen insider activity provides valuable insight into whether Protagenic Therapeutics is net buyers or sellers over its current business cycle. Note, Protagenic Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protagenic Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Garo Armen few days ago Acquisition by Garo Armen of 3080 shares of Agenus at 5.31 subject to Rule 16b-3 | ||
Garo Armen over a month ago Acquisition by Garo Armen of 27163 shares of Agenus at 0.55 subject to Rule 16b-3 | ||
Garo Armen over a month ago Acquisition by Garo Armen of 22136 shares of Agenus at 0.67 subject to Rule 16b-3 | ||
Garo Armen over six months ago Purchase by Garo Armen of 100000 shares of Mink Therapeutics |
Protagenic Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4578) % which means that it has lost $0.4578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9448) %, meaning that it created substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to rise to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 12 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.Similar Executives
Found 7 records | CHAIRMAN Age | ||
Michael Wyzga | X4 Pharmaceuticals | 63 | |
Thomas Hecht | Affimed NV | N/A | |
Michael Forer | ADC Therapeutics SA | 55 | |
Richard Miller | Corvus Pharmaceuticals | 66 | |
Ron Squarer | ADC Therapeutics SA | 54 | |
Jonathan Knowles | Adaptimmune Therapeutics Plc | 68 | |
Peter Fellner | Mereo BioPharma Group | 73 |
Management Performance
Return On Equity | -0.94 | ||||
Return On Asset | -0.46 |
Protagenic Therapeutics Leadership Team
Elected by the shareholders, the Protagenic Therapeutics' board of directors comprises two types of representatives: Protagenic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagenic. The board's role is to monitor Protagenic Therapeutics' management team and ensure that shareholders' interests are well served. Protagenic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagenic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert MD, Chief Director | ||
Gregory Ekizian, Independent Director | ||
Robert Stein, Director | ||
Garo Armen, Chairman of the Board | ||
Brian Corvese, Independent Director | ||
MD CFA, CFO Secretary | ||
Khalil Barrage, Independent Director | ||
David Lovejoy, Scientific Officer | ||
Andrew Slee, Chief Officer | ||
Alexander Arrow, Acting CFO | ||
Joshua Silverman, Director |
Protagenic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagenic Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.94 | ||||
Return On Asset | -0.46 | ||||
Current Valuation | 2.91 M | ||||
Shares Outstanding | 4.44 M | ||||
Shares Owned By Insiders | 21.83 % | ||||
Shares Owned By Institutions | 7.96 % | ||||
Number Of Shares Shorted | 11.33 K | ||||
Price To Earning | 9.43 X | ||||
Price To Book | 1.74 X | ||||
EBITDA | (4.5 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagenic Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagenic Therapeutics' short interest history, or implied volatility extrapolated from Protagenic Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagenic Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Protagenic Stock analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Return On Assets (0.46) | Return On Equity (0.94) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.